These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23553067)

  • 41. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
    Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
    Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
    Kubota Y; Fujita KI; Takahashi T; Sunakawa Y; Ishida H; Hamada K; Ichikawa W; Tsunoda T; Shimada K; Masuo Y; Kato Y; Sasaki Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):586-595. PubMed ID: 32034953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data.
    Bekaii-Saab T; Khan N; Ostojic H; Jiao X; Chen G; Lin W; Bruno A
    BMC Cancer; 2024 Aug; 24(1):939. PubMed ID: 39095766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
    Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer.
    Kim ST; Kim TW; Kim KP; Kim TY; Han SW; Lee JY; Lim SH; Lee MY; Kim H; Park YS
    Cancer Res Treat; 2015 Oct; 47(4):790-5. PubMed ID: 25672574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
    Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
    Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer.
    Carter NJ
    Drugs Aging; 2014 Jan; 31(1):67-78. PubMed ID: 24276917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
    Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
    Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
    Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
    Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
    Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
    Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
    Belum VR; Wu S; Lacouture ME
    Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.